FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101472589> ?p ?o ?g. }

• W2101472589 endingPage "15" @default.
• W2101472589 startingPage "15" @default.
• W2101472589 abstract "This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir (CPI/r) in HIV infected patients that were previously exposed to antiretroviral therapy in the Netherlands.We compared the projected lifetime costs and effects of two theoretical groups of 1000 patients, one receiving a standard of care regimen with TPV/r as a component and the other receiving a standard of care regimen with CPI/r. A 3-stage Markov model was formulated to represent three different consecutive HAART regimens. The model uses 12 health states based on viral load and CD4+ count to simulate disease progression. The transition probabilities for the Markov model were derived from a United States cohort of treatment experienced HIV patients. Furthermore, the study design was based on 48-week data from the RESIST-2 clinical trial and local Dutch costing data. Cost and health effects were discounted at 4% and 1.5% respectively according to the Dutch guideline. The analysis was conducted from the Dutch healthcare perspective using 2006 unit cost prices.Our model projects an accumulated discounted cost to the Dutch healthcare system per patient receiving the TPV/r regimen of euro167,200 compared to euro145,400 for the CPI/r regimen. This results in an incremental cost of euro21,800 per patient. The accumulated discounted effect is 7.43 life years or 6.31 quality adjusted life years (QALYs) per patient receiving TPV/r, compared to 6.91 life years or 5.80 QALYs per patient receiving CPI/r. This translates into an incremental effect of TPV/r over CPI/r of 0.52 life years gained (LYG) or 0.51 QALYs gained. The corresponding incremental cost effectiveness ratios (iCERs) are euro41,600 per LYG and euro42,500 per QALY.We estimated the iCER for TPV/r compared to CPI/r at approximately euro40,000 in treatment experienced HIV-1 infected patients in the Netherlands. This ratio may well be in range of what is acceptable and warrants reimbursement for new drug treatments in the Netherlands, in particular in therapeutic areas as end-stage oncology and HIV and other last-resort health-care interventions." @default.
• W2101472589 created "2016-06-24" @default.
• W2101472589 creator A5007814549 @default.
• W2101472589 creator A5013124915 @default.
• W2101472589 creator A5016565734 @default.
• W2101472589 creator A5043515095 @default.
• W2101472589 creator A5052383774 @default.
• W2101472589 creator A5070794861 @default.
• W2101472589 creator A5075477479 @default.
• W2101472589 creator A5086485134 @default.
• W2101472589 creator A5090843545 @default.
• W2101472589 date "2007-01-01" @default.
• W2101472589 modified "2023-10-09" @default.
• W2101472589 title "Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands" @default.
• W2101472589 cites W1984717160 @default.
• W2101472589 cites W1984904918 @default.
• W2101472589 cites W1994222210 @default.
• W2101472589 cites W1995895570 @default.
• W2101472589 cites W1999076794 @default.
• W2101472589 cites W2003479257 @default.
• W2101472589 cites W2014746968 @default.
• W2101472589 cites W2018112385 @default.
• W2101472589 cites W2025685004 @default.
• W2101472589 cites W2033004195 @default.
• W2101472589 cites W2038002163 @default.
• W2101472589 cites W2093002176 @default.
• W2101472589 cites W2099509337 @default.
• W2101472589 cites W2109525043 @default.
• W2101472589 cites W2127840648 @default.
• W2101472589 cites W2128877806 @default.
• W2101472589 cites W2133338060 @default.
• W2101472589 cites W2144984387 @default.
• W2101472589 cites W2162815450 @default.
• W2101472589 cites W2318289184 @default.
• W2101472589 cites W3191422891 @default.
• W2101472589 doi "https://doi.org/10.1186/1478-7547-5-15" @default.
• W2101472589 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2211743" @default.
• W2101472589 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18034881" @default.
• W2101472589 hasPublicationYear "2007" @default.
• W2101472589 type Work @default.
• W2101472589 sameAs 2101472589 @default.
• W2101472589 citedByCount "9" @default.
• W2101472589 countsByYear W21014725892012 @default.
• W2101472589 countsByYear W21014725892013 @default.
• W2101472589 countsByYear W21014725892015 @default.
• W2101472589 crossrefType "journal-article" @default.
• W2101472589 hasAuthorship W2101472589A5007814549 @default.
• W2101472589 hasAuthorship W2101472589A5013124915 @default.
• W2101472589 hasAuthorship W2101472589A5016565734 @default.
• W2101472589 hasAuthorship W2101472589A5043515095 @default.
• W2101472589 hasAuthorship W2101472589A5052383774 @default.
• W2101472589 hasAuthorship W2101472589A5070794861 @default.
• W2101472589 hasAuthorship W2101472589A5075477479 @default.
• W2101472589 hasAuthorship W2101472589A5086485134 @default.
• W2101472589 hasAuthorship W2101472589A5090843545 @default.
• W2101472589 hasBestOaLocation W21014725891 @default.
• W2101472589 hasConcept C112930515 @default.
• W2101472589 hasConcept C126322002 @default.
• W2101472589 hasConcept C142462285 @default.
• W2101472589 hasConcept C160735492 @default.
• W2101472589 hasConcept C162324750 @default.
• W2101472589 hasConcept C177713679 @default.
• W2101472589 hasConcept C203014093 @default.
• W2101472589 hasConcept C2779298103 @default.
• W2101472589 hasConcept C2781143361 @default.
• W2101472589 hasConcept C2781413609 @default.
• W2101472589 hasConcept C2993143319 @default.
• W2101472589 hasConcept C3013748606 @default.
• W2101472589 hasConcept C3019080777 @default.
• W2101472589 hasConcept C50522688 @default.
• W2101472589 hasConcept C64332521 @default.
• W2101472589 hasConcept C71924100 @default.
• W2101472589 hasConceptScore W2101472589C112930515 @default.
• W2101472589 hasConceptScore W2101472589C126322002 @default.
• W2101472589 hasConceptScore W2101472589C142462285 @default.
• W2101472589 hasConceptScore W2101472589C160735492 @default.
• W2101472589 hasConceptScore W2101472589C162324750 @default.
• W2101472589 hasConceptScore W2101472589C177713679 @default.
• W2101472589 hasConceptScore W2101472589C203014093 @default.
• W2101472589 hasConceptScore W2101472589C2779298103 @default.
• W2101472589 hasConceptScore W2101472589C2781143361 @default.
• W2101472589 hasConceptScore W2101472589C2781413609 @default.
• W2101472589 hasConceptScore W2101472589C2993143319 @default.
• W2101472589 hasConceptScore W2101472589C3013748606 @default.
• W2101472589 hasConceptScore W2101472589C3019080777 @default.
• W2101472589 hasConceptScore W2101472589C50522688 @default.
• W2101472589 hasConceptScore W2101472589C64332521 @default.
• W2101472589 hasConceptScore W2101472589C71924100 @default.
• W2101472589 hasIssue "1" @default.
• W2101472589 hasLocation W21014725891 @default.
• W2101472589 hasLocation W21014725892 @default.
• W2101472589 hasLocation W21014725893 @default.
• W2101472589 hasLocation W21014725894 @default.
• W2101472589 hasLocation W21014725895 @default.
• W2101472589 hasLocation W21014725896 @default.
• W2101472589 hasOpenAccess W2101472589 @default.
• W2101472589 hasPrimaryLocation W21014725891 @default.
• W2101472589 hasRelatedWork W1986196348 @default.

• next